Topics
rivaroxabanChemical substance
apixabanChemical substance
atrial fibrillationDisease
edoxabanChemical substance
factor XaBiomolecule
warfarinChemical substance
Objective: To evaluate the overall efficacy, advantages, and disadvantages of treatment with direct factor Xa inhibitors as compared to warfarin in the prevention of stroke in patients with atrial fibrillation. Methods: A quantitative meta-analysis was performed on three separate studies, each of which evaluated the efficacy and safety outcomes of a direct factor Xa inhibitor versus warfarin in preventing stroke in patients with atrial fibrillation. The direct factor Xa inhibitors that were evaluated included apixaban, edoxaban, and rivaroxaban. Results: The direct factor Xa inhibitors were found to be as effective, and in some cases more effective, than warfarin in preventing stroke in patients with atrial fibrillation. In addition, the di...
Purpose: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all ...
International audienceBACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithro...
International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...
Atrial fibrillation is a common cause for stroke. Vitamin K antagonists such as warfarin are an effe...
BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial ...
BackgroundVitamin K antagonists are highly effective in preventing stroke in patients with atrial fi...
Objective: To do an indirect comparison analysis of apixaban against dabigatran etexilate (2 doses) ...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillat...
Background: Various treatment strategies to treat AF and reduce its complications have been develope...
Background: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...
Background and purpose: The use of oral anticoagulant therapy for stroke prevention in atrial fibril...
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARIS...
This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), riva...
Purpose: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all ...
International audienceBACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithro...
International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...
Atrial fibrillation is a common cause for stroke. Vitamin K antagonists such as warfarin are an effe...
BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial ...
BackgroundVitamin K antagonists are highly effective in preventing stroke in patients with atrial fi...
Objective: To do an indirect comparison analysis of apixaban against dabigatran etexilate (2 doses) ...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillat...
Background: Various treatment strategies to treat AF and reduce its complications have been develope...
Background: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...
Background and purpose: The use of oral anticoagulant therapy for stroke prevention in atrial fibril...
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARIS...
This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), riva...
Purpose: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all ...
International audienceBACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithro...
International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...
Add to ORKG